Dragan 2013.

Trial name or title	The impact of EPA and DHA supplementation on the content of lipids in the pregnant women and the fetus
Methods	RCT
Participants	Recruitment target: 87 women. Inclusion criteria: healthy; with a singleton pregnancy; BMI < 25 kg/m2; willing to provide informed consent. Exclusion criteria: pregnancy terminated as preterm birth; with chronic illness; gestational diabetes mellitus or pre‐eclampsia. Setting: Bosnia, Herzegovina.
Interventions	Intervention group 360 mg EPA (eicosapentanoic fatty acid) and 240 mg DHA (docosahexanoic fatty acid) per day during pregnancy, from baseline (14th week of gestation) until birth. Control group No supplementation of omega‐3 fatty acids during pregnancy.
Outcomes	Primary outcomes: concentration of omega‐3 fatty acids in total serum lipids, measured using gas chromatography at the end of pregnancy; concentration of omega‐3 fatty acids in umbilical vein serum, measured using gas chromatography at time of birth; concentration of monounsaturated fatty acids in serum total lipids of umbilical vein serum, measured by gas chromatography at time of birth; concentration of monounsaturated fatty acids in serum total lipids of the mother's serum, measured by gas chromatography at the end of pregnancy; weight of mother, measured by weighing scale at recruitment, 20th week of gestation, 30th week of gestation and before birth. Secondary outcomes: weight of mother (measured at recruitment, 20 weeks of gestation, 30 weeks of gestation and before birth).
Starting date	May 2013
Contact information	Dr Soldo Dragon, Department of Obstetrics and Gynecology School of Medicine Mostar, Kralja Tvrtka, b.b. Mostar 88000, Bosnia, Herzegovina. E‐mail:dragan.soldo3@tel.net.ba
Notes	Funding and collaborators: investigator initiated and funded.